Key Highlights Ligand Pharmaceuticals to acquire APEIRON Biologics AG for $100 million in cash. QARZIBA® (dinutuximab beta), an immunotherapy for high-risk…
Key Highlights Proactive identification of high-risk individuals through predictive modeling Hyper-personalized care planning based on unique individual profiles Continuous analysis…